These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1343 related articles for article (PubMed ID: 27655849)

  • 41. The anti-tumor role of NK cells in vivo pre-activated and re-stimulated by interleukins in acute lymphoblastic leukemia.
    Jin F; Lin H; Gao S; Hu Z; Zuo S; Sun L; Jin C; Li W; Yang Y
    Oncotarget; 2016 Nov; 7(48):79187-79202. PubMed ID: 27816971
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.
    Hallner A; Bernson E; Hussein BA; Ewald Sander F; Brune M; Aurelius J; Martner A; Hellstrand K; Thorén FB
    Blood; 2019 Mar; 133(13):1479-1488. PubMed ID: 30647027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
    Gang M; Marin ND; Wong P; Neal CC; Marsala L; Foster M; Schappe T; Meng W; Tran J; Schaettler M; Davila M; Gao F; Cashen AF; Bartlett NL; Mehta-Shah N; Kahl BS; Kim MY; Cooper ML; DiPersio JF; Berrien-Elliott MM; Fehniger TA
    Blood; 2020 Nov; 136(20):2308-2318. PubMed ID: 32614951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
    Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
    Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful Transfer of Umbilical Cord Blood CD34
    Dolstra H; Roeven MWH; Spanholtz J; Hangalapura BN; Tordoir M; Maas F; Leenders M; Bohme F; Kok N; Trilsbeek C; Paardekooper J; van der Waart AB; Westerweel PE; Snijders TJF; Cornelissen J; Bos G; Pruijt HFM; de Graaf AO; van der Reijden BA; Jansen JH; van der Meer A; Huls G; Cany J; Preijers F; Blijlevens NMA; Schaap NM
    Clin Cancer Res; 2017 Aug; 23(15):4107-4118. PubMed ID: 28280089
    [No Abstract]   [Full Text] [Related]  

  • 47. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.
    Sanchez-Correa B; Morgado S; Gayoso I; Bergua JM; Casado JG; Arcos MJ; Bengochea ML; Duran E; Solana R; Tarazona R
    Cancer Immunol Immunother; 2011 Aug; 60(8):1195-205. PubMed ID: 21644031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
    Jiang W; Zhang C; Tian Z; Zhang J
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural killer cell receptor repertoire is comparable amongst newly diagnosed acute myeloid leukemia of different French-American-British subtypes, risk categories and chemosensitivities.
    Ho X; Fook-Chong S; Linn YC
    Leuk Lymphoma; 2014 Feb; 55(2):342-8. PubMed ID: 23550989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.
    Wang Y; Chen C; Dong F; Ma S; Xu J; Gong Y; Cheng H; Zhou Y; Cheng T; Hao S
    Sci China Life Sci; 2015 Dec; 58(12):1288-98. PubMed ID: 26588911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.
    Schlegel P; Ditthard K; Lang P; Mezger M; Michaelis S; Handgretinger R; Pfeiffer M
    J Immunol Res; 2015; 2015():473175. PubMed ID: 26236752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
    Front Immunol; 2021; 12():665541. PubMed ID: 33986753
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications.
    Terrén I; Orrantia A; Astarloa-Pando G; Amarilla-Irusta A; Zenarruzabeitia O; Borrego F
    Front Immunol; 2022; 13():884648. PubMed ID: 35603208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
    Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
    Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors.
    Szczepanski MJ; Szajnik M; Welsh A; Foon KA; Whiteside TL; Boyiadzis M
    Cancer Immunol Immunother; 2010 Jan; 59(1):73-9. PubMed ID: 19526239
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
    Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
    Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia.
    Bou-Tayeh B; Laletin V; Salem N; Just-Landi S; Fares J; Leblanc R; Balzano M; Kerdiles YM; Bidaut G; Hérault O; Olive D; Aurrand-Lions M; Walzer T; Nunès JA; Fauriat C
    Front Immunol; 2021; 12():730970. PubMed ID: 34975835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial.
    Kottaridis PD; North J; Tsirogianni M; Marden C; Samuel ER; Jide-Banwo S; Grace S; Lowdell MW
    PLoS One; 2015; 10(6):e0123416. PubMed ID: 26062124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells.
    Lion E; Smits EL; Berneman ZN; Van Tendeloo VF
    Leuk Res; 2009 Apr; 33(4):539-46. PubMed ID: 18845337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
    Carlsten M; Järås M
    Front Immunol; 2019; 10():2357. PubMed ID: 31681270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.